
    
      The decision was taken to halt study enrollment with Cohort #3 in Phase Ib. Therefore,
      activities for the planned Phase II were not initiated.

      This decision to stop further development of this combination was taken due to the challenge
      for enrollment in this very rare patient population along with the rapidly evolving disease
      landscape setting.
    
  